RT Journal Article
SR Electronic
T1 High-throughput immunoassays for SARS-CoV-2 – considerable differences in performance when comparing three methods
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20106294
DO 10.1101/2020.05.22.20106294
A1 Ekelund, Oskar
A1 Ekblom, Kim
A1 Somajo, Sofia
A1 Pattison-Granberg, Johanna
A1 Olsson, Karl
A1 Petersson, Annika
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.22.20106294.abstract
AB The recently launched high-throughput assays for the detection of antibodies against SARS-CoV-2 may change the diagnostic strategies for COVID-19. This study aimed at investigating the performance of three novel high-throughput assays on Abbott Architect, Roche Cobas, and DiaSorin Liaison platforms. In addition, we evaluated a rapid lateral flow test from Dynamiker Biotechnology. A panel consisting of 133 samples including 100 pre-pandemic samples, 20 samples from SARS-CoV-2 PCR positive individuals and 13 possible crossreactive samples were used. Sensitivity and specificity in this study were equivalent with manufacturers’ data from Abbott and Roche but differed from those reported from DiaSorin and Dynamiker Biotechnology. The results suggest that the assays from Abbott and Roche could be considered in clinical use for individual patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Swedish Ethical Review Agency, the study did not require ethics approval according to their guidelines (nor to the Swedish Ethical Review Act).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from the corresponding author on a reasonable request.